Latest Breaking News On - Jiangsu alphamab - Page 1 : comparemela.com

Alphamab Oncology Reports Full Year 2023 Financial Results and Business Highlights

SUZHOU, China, March 29, 2024 /PRNewswire/ Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year ended December 31, 2023 and

Hong kongUnited statesJiangsu alphamabAsia pacificPharmaceuticals incChinese pharmaceutical innovative enterprisesChina national medical products administrationHong kong stock exchangeDrug administrationBellberry human research ethics committeeSociety for immunotherapy of cancerChinese pharmaceutical listed companiesEuropean society for medical oncology congressNature communicationsAmerican association for cancer researchAlphamab oncology

Glenmark inks licensing pact with Jiangsu Alphamab, 3D Medicines for cancer drug

Under the agreement, Glenmark will get the license for KN035 (Envafolimab) in India, Asia Pacific, the Middle East, Africa, Russia, CIS, and Latin America, the company said in a statement.

United statesJiangsu alphamabTracon pharmaGlenn saldanhaAsia pacificGlenmark pharmaceuticalsJiangsu alphamab biopharmaceuticals coNational medical products administration chineseDrug administrationGlenmark pharmaceuticals ltd onD medicines beijing co ltdPharmaceuticals ltdMiddle eastLatin americaPharmaceuticals chairmanManaging glenn saldanha

Stock Market Live Updates 25 January 2024: Updates: Sensex slips below 71,000, Nifty struggles as global headwinds impact Indian markets

Stock Market Live Updates 25 January 2024: Updates: Sensex slips below 71,000, Nifty struggles as global headwinds impact Indian markets
thehindubusinessline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindubusinessline.com Daily Mail and Mail on Sunday newspapers.

Tamil naduAndhra pradeshRed seaDjibouti generalWest bengalUnited statesUnited kingdomMadhya pradeshShreyansh shahSea houthiHimanshu singhPradhan mantri suryodaya yojanaPan gongshengNova agritechTata metaliksKausal jadia

Latest News | Glenmark Inks Licensing Pact with Jiangsu Alphamab, 3D Medicines for Cancer Drug

Get latest articles and stories on Latest News at LatestLY. Glenmark Pharmaceuticals Ltd on Thursday said its arm Glenmark Specialty S A (GSSA) has signed a license agreement with Jiangsu Alphamab Biopharmaceuticals Co and 3D Medicines (Beijing) Co Ltd for KN035 (Envafolimab), used in cancer treatment. Latest News | Glenmark Inks Licensing Pact with Jiangsu Alphamab, 3D Medicines for Cancer Drug.

New delhiUnited statesJiangsu alphamabAsia pacificBharat ratnaGlenn saldanhaKarpoori thakurTracon pharmaD medicines beijing co ltdNational medical products administration chineseGlenmark pharmaceuticals ltd onJiangsu alphamab biopharmaceuticals coDrug administrationGlenmark pharmaceuticalsGlenmark pharmaceuticals ltdMiddle east

Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World

Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS,.

United statesAsia pacificJiangsu alphamabGlenn saldanhaTracon pharmaGlenmark pharmaceuticals ltdNational medical products administration chineseMiddle eastGlenmark pharmaceuticalsLatin americaTerritory the licensorswillLicense agreementManaging directorNational medical products administrationBreakthrough therapieEmerging markets